Status:
COMPLETED
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients
Lead Sponsor:
Ricardo Pereira Mestre
Collaborating Sponsors:
Institute of Oncology Research (IOR)
Istituto Cantonale di Patologia
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
The study includes 2 sub-projects. Sub-project 1: The aim is to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2 entry and spreading in the local population of Ticin...
Detailed Description
Sub-project 1: This is an observational retrospective study that aims to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2 entry and spreading in the local population...
Eligibility Criteria
Inclusion
- Sub-project 1
- Availability of RNA extracted from nasopharyngeal swabs taken from subjects tested for COVID-19;
- Subject is aged 18 years or over;
- Written informed consent (for SARS-CoV-2 positive patients only; see §5 for further details).
Exclusion
- \- Documented refusal.
- Sub-project 2
- Inclusion Criteria:
- Female and male hospitalized SARS-CoV-2 patients;
- Patient is aged 18 years or over;
- Availability of archival tissue samples collected at any time before SARS-CoV-2 infection for any clinical reason;
- Clinico-pathological characteristics of the COVID-19 and clinical outcomes recorded in the EOC and Clinica Luganese Moncucco database;
- Written informed consent (see §5 for further details).
Key Trial Info
Start Date :
June 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 21 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04516850
Start Date
June 8 2020
End Date
February 21 2023
Last Update
April 25 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Institute of Southern Switzerland (IOSI)
Bellinzona, Switzerland, 6500
2
Clinica Luganese Moncucco
Lugano, Switzerland, 6900